ArticleExperimental hematology & oncology2014
Novel agents and strategies for overcoming EGFR TKIs resistance.
Article in Experimental hematology & oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Dickkopf-1 promotes tumor progression of gefitinib- resistant non-small cell lung cancer through cancer cell-fibroblast interactions.Experimental hematology & oncology · 2025Article
- Design, Synthesis and Biological Evaluation of Multi-Target Anti-Cancer Agent PYR26.International journal of molecular sciences · 2023Article
- EGFR is a potential dual molecular target for cancer and Alzheimer's disease.Frontiers in pharmacology · 2023Review
- MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors.Experimental hematology & oncology · 2021Article
- Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors.Molecules (Basel, Switzerland) · 2019Article
- Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.Molecular medicine reports · 2018Article
- Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.Molecular cancer · 2018Review
- The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis.OncoTargets and therapy · 2018Article
- Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.Acta pharmacologica Sinica · 2017Article
- Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.Frontiers of medicine · 2016Review
- CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer.International journal of oncology · 2016Article
- Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.Journal of hematology & oncology · 2016Article
- Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.Translational lung cancer research · 2016Review
- EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.Journal of hematology & oncology · 2016Review
- Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study.Thoracic cancer · 2016Article
- Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.Journal of hematology & oncology · 2016Review
- Second- and third-generation ALK inhibitors for non-small cell lung cancer.Journal of hematology & oncology · 2016Review
- Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation.Journal of hematology & oncology · 2015Article
- NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin.Journal of hematology & oncology · 2015Article
- Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target, EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR mutations, which has been a major breakthrough for lung cancer treatment.. The progression-free survival (PFS) of patients with EGFR mutations treated with EGFR TKIs is significantly prolonged compared with that of patients who underwent standard chemotherapy. However, all patients who initially respond to EGFR TKIs eventually develop acquired resistance (AR). Many small molecule agents and monoclonal antibodies (McAb) targeting signaling pathways are potential therapeutic regimens for overcoming resistance, and various therapeutic strategies are used in clinical practice. Here we review the novel agents and therapeutic strategies for overcoming AR to EGFR TKIs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.